Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jun 13, 2023 5:21pm
223 Views
Post# 35494670

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Who knows what ? When or how?

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Who knows what ? When or how?

Actually we are two weeks closer to the Pancreatic cancer trial update.
.....You know, the one with Roche, that brought to attention immediately gaining FDA fast track approval & moving the trial to phase 2b?
The same trial that indicated results 3x better than the existing standard of care.
Including one complete remission.
The share price? 
I recall Mr. Buck Henry , advised everyone to sell on Friday & buy back in October?
please do some reading. They are expected to announce updates to the panc cancer & other Goblet results, alongside Tecentriq ( Roche), second half of this year.
That could be anytime between now & Dec 31.
Should the additional pancreatic results even come close to the run- in trial? The SP will be well above any spikes we have seen lately.
enjoy you days all...
 

<< Previous
Bullboard Posts
Next >>